Associations of selected variables with moderate or severe COVID-19, decision to forgo ICU care, and mortality
| . | COVID-19 severity of moderate or severe* (n = 245), n/N (%) . | ICU forgone in favor of palliative care* (n = 244), n/N (%) . | Mortality (n = 245), n/N (%) . |
|---|---|---|---|
| Age, y | |||
| <19 | 4/19 (21) | 1/18 (6) | 2/18 (11) |
| 19-39 | 16/31 (52) | 0/30 (0) | 4/30 (13) |
| 40-70 | 77/104 (74) | 13/104 (13) | 28/105 (27) |
| >70 | 66/86 (77) | 25/87 (29) | 34/87 (39) |
| No response | 5/5 (100) | 1/5 (20) | 2/5 (40) |
| Sex | |||
| Male | 98/140 (70) | 30/141 (21) | 49/141 (35) |
| Female | 65/100 (65) | 10/98 (10) | 19/99 (19) |
| No response | 5/5 (100) | 0/5 (0) | 2/5 (40) |
| Race | |||
| Asian | 22/28 (79) | 10/29 (34) | 12/29 (41) |
| Black/African American | 22/34 (65) | 1/35 (3) | 6/35 (17) |
| White | 66/104 (63) | 20/102 (20) | 29/102 (28) |
| Hispanic/Latino/other | 39/57 (68) | 18/57 (32) | 18/58 (31) |
| Unknown/no response | 19/22 (86) | 3/22 (11) | 5/21 (24) |
| Comorbidity | |||
| Diabetes | 36/45 (80) | 10/46 (22) | 15/46 (33) |
| Hypertension | 51/72 (71) | 9/75 (12) | 22/75 (29) |
| Heart disease | 25/34 (74) | 10/35 (29) | 19/35 (54) |
| Lung disease | 15/23 (65) | 5/24 (21) | 9/24 (38) |
| Kidney disease | 23/27 (85) | 8/28 (29) | 13/28 (46) |
| Other | 36/46 (78) | 9/46 (20) | 16/46 (35) |
| ≥1 comorbidity | 96/134 (72) | 28/137 (20) | 45/137 (33) |
| No response | 72/111 (65) | 12/107 (11) | 25/108 (23) |
| Smoking status | |||
| Current | 9/10 (90) | 1/10 (10) | 5/10 (50) |
| Former | 34/52 (65) | 5/54(9) | 13/54 (24) |
| Never | 64/109 (59) | 15/106 (14) | 21/107 (20) |
| Unknown | 16/18 (89) | 5/18 (28) | 6/18 (33) |
| No response | 45/56 (80) | 14/56 (25) | 25/56 (45) |
| Hematologic malignancy | |||
| Acute leukemia | 50/80 (63) | 16/79 (20) | 26/79 (33) |
| CLL | 21/29 (72) | 3/29 (10) | 8/29 (28) |
| HL | 5/11 (45) | 0/11 (0) | 4/11 (36) |
| NHL | 47/68 (69) | 10/67 (15) | 16/67 (24) |
| MPN | 19/24 (79) | 4/23 (17) | 6/24 (25) |
| MM or AL amyloid | 30/37 (81) | 7/39 (18) | 11/39 (28) |
| All respondents | 168/245 (69) | 40/244 (16) | 70/245 (29) |
| Treatment received in year before COVID-19 diagnosis among treated patients | |||
| Cytotoxic chemotherapy | 60/82 (73) | 11/83 (13) | 30/83 (36) |
| Immunotherapy | 31/35 (89) | 10/35 (29) | 15/35 (43) |
| Targeted therapy | 40/52 (77) | 6/52 (12) | 16/53 (30) |
| Other | 73/96 (75) | 20/95 (21) | 31/95 (33) |
| Unknown | 1/1 (100) | 0/1 (0) | 0/1 (0) |
| All respondents | 130/179 (73) | 31/177 (18) | 59/178 (33) |
| Pre–COVID-19 prognosis, mo | |||
| ≤12 | 38/46 (83) | 21/45 (47) | 28/45 (62) |
| >12 | 102/153 (67) | 17/151 (11) | 34/152 (22) |
| No response | 28/46 (61) | 2/48 (4) | 8/48 (17) |
| Malignancy status | |||
| Initial treatment | 42/58 (72) | 12/59 (20) | 19/59 (32) |
| Remission | 50/87 (57) | 7/87 (8) | 16/87 (18) |
| Relapsed/refractory | 28/34 (82) | 10/34 (29) | 16/34 (47) |
| Stable, not in remission | 37/54 (69) | 9/52 (17) | 16/53 (30) |
| No response | 11/12 (92) | 2/12 (17) | 3/12 (25) |
| Mortality | |||
| Recovered | 94/166 (57) | 5/167 (3) | |
| Death | 68/70 (97) | 35/70 (50) | |
| Unknown | 5/6 (83) | 5/7 (71) | |
| No response | 1/3 (33) | 0/0 | |
| ICU forgone in favor of palliative care | |||
| Yes | 37/40 (93) | 35/40 (88) | |
| No | 123/192 (64) | 33/194 (17) | |
| Unknown | 7/9 (78) | 2/10 (20) | |
| No response | 1/4 (25) | 0/1 (0) |
| . | COVID-19 severity of moderate or severe* (n = 245), n/N (%) . | ICU forgone in favor of palliative care* (n = 244), n/N (%) . | Mortality (n = 245), n/N (%) . |
|---|---|---|---|
| Age, y | |||
| <19 | 4/19 (21) | 1/18 (6) | 2/18 (11) |
| 19-39 | 16/31 (52) | 0/30 (0) | 4/30 (13) |
| 40-70 | 77/104 (74) | 13/104 (13) | 28/105 (27) |
| >70 | 66/86 (77) | 25/87 (29) | 34/87 (39) |
| No response | 5/5 (100) | 1/5 (20) | 2/5 (40) |
| Sex | |||
| Male | 98/140 (70) | 30/141 (21) | 49/141 (35) |
| Female | 65/100 (65) | 10/98 (10) | 19/99 (19) |
| No response | 5/5 (100) | 0/5 (0) | 2/5 (40) |
| Race | |||
| Asian | 22/28 (79) | 10/29 (34) | 12/29 (41) |
| Black/African American | 22/34 (65) | 1/35 (3) | 6/35 (17) |
| White | 66/104 (63) | 20/102 (20) | 29/102 (28) |
| Hispanic/Latino/other | 39/57 (68) | 18/57 (32) | 18/58 (31) |
| Unknown/no response | 19/22 (86) | 3/22 (11) | 5/21 (24) |
| Comorbidity | |||
| Diabetes | 36/45 (80) | 10/46 (22) | 15/46 (33) |
| Hypertension | 51/72 (71) | 9/75 (12) | 22/75 (29) |
| Heart disease | 25/34 (74) | 10/35 (29) | 19/35 (54) |
| Lung disease | 15/23 (65) | 5/24 (21) | 9/24 (38) |
| Kidney disease | 23/27 (85) | 8/28 (29) | 13/28 (46) |
| Other | 36/46 (78) | 9/46 (20) | 16/46 (35) |
| ≥1 comorbidity | 96/134 (72) | 28/137 (20) | 45/137 (33) |
| No response | 72/111 (65) | 12/107 (11) | 25/108 (23) |
| Smoking status | |||
| Current | 9/10 (90) | 1/10 (10) | 5/10 (50) |
| Former | 34/52 (65) | 5/54(9) | 13/54 (24) |
| Never | 64/109 (59) | 15/106 (14) | 21/107 (20) |
| Unknown | 16/18 (89) | 5/18 (28) | 6/18 (33) |
| No response | 45/56 (80) | 14/56 (25) | 25/56 (45) |
| Hematologic malignancy | |||
| Acute leukemia | 50/80 (63) | 16/79 (20) | 26/79 (33) |
| CLL | 21/29 (72) | 3/29 (10) | 8/29 (28) |
| HL | 5/11 (45) | 0/11 (0) | 4/11 (36) |
| NHL | 47/68 (69) | 10/67 (15) | 16/67 (24) |
| MPN | 19/24 (79) | 4/23 (17) | 6/24 (25) |
| MM or AL amyloid | 30/37 (81) | 7/39 (18) | 11/39 (28) |
| All respondents | 168/245 (69) | 40/244 (16) | 70/245 (29) |
| Treatment received in year before COVID-19 diagnosis among treated patients | |||
| Cytotoxic chemotherapy | 60/82 (73) | 11/83 (13) | 30/83 (36) |
| Immunotherapy | 31/35 (89) | 10/35 (29) | 15/35 (43) |
| Targeted therapy | 40/52 (77) | 6/52 (12) | 16/53 (30) |
| Other | 73/96 (75) | 20/95 (21) | 31/95 (33) |
| Unknown | 1/1 (100) | 0/1 (0) | 0/1 (0) |
| All respondents | 130/179 (73) | 31/177 (18) | 59/178 (33) |
| Pre–COVID-19 prognosis, mo | |||
| ≤12 | 38/46 (83) | 21/45 (47) | 28/45 (62) |
| >12 | 102/153 (67) | 17/151 (11) | 34/152 (22) |
| No response | 28/46 (61) | 2/48 (4) | 8/48 (17) |
| Malignancy status | |||
| Initial treatment | 42/58 (72) | 12/59 (20) | 19/59 (32) |
| Remission | 50/87 (57) | 7/87 (8) | 16/87 (18) |
| Relapsed/refractory | 28/34 (82) | 10/34 (29) | 16/34 (47) |
| Stable, not in remission | 37/54 (69) | 9/52 (17) | 16/53 (30) |
| No response | 11/12 (92) | 2/12 (17) | 3/12 (25) |
| Mortality | |||
| Recovered | 94/166 (57) | 5/167 (3) | |
| Death | 68/70 (97) | 35/70 (50) | |
| Unknown | 5/6 (83) | 5/7 (71) | |
| No response | 1/3 (33) | 0/0 | |
| ICU forgone in favor of palliative care | |||
| Yes | 37/40 (93) | 35/40 (88) | |
| No | 123/192 (64) | 33/194 (17) | |
| Unknown | 7/9 (78) | 2/10 (20) | |
| No response | 1/4 (25) | 0/1 (0) |
AL, amyloid light chain; CLL, chronic lymphocytic leukemia; HL, Hodgkin lymphoma; MM, multiple myeloma; MPN, myeloproliferative neoplasm; NHL, non-Hodgkin lymphoma.
Cases were included for an outcome only if information about that outcome was reported.